Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2021-12-21
Target enrollment:
Participant gender:
Summary
The death of prostate cancer patients is mainly due to metastatic castration-resistant
prostate cancer. Though some new therapies has been tried to prolong the life-span of mCRPC
patients, a dilemma was encountered for the drug-resistance. The PSMA RLT has been tested its
efficacy and safety for the therapy of these patients. In our clinical trial, a new PSMA
ligand will been used to be labeled with Ac225. This will be a prospective pilot clinical
trial. 20 mCRPC patients who was incapable of 2rd ADT or chemotherapy will be recruited in
this clinical tiral. The efficacy and safety of 225Ac-PSMA will be evaluated after the
administration.
Phase:
Early Phase 1
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine